1-10 of 10
Vickie Lu
Close
Sort by
Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F Apperley
Journal: Blood
Blood (2023) 142 (Supplement 1): 3164.
https://doi.org/10.1182/blood-2023-178790
Published: 2023
Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge E. Cortes, Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F. Apperley
Journal: Blood
Blood (2022) 140 (Supplement 1): 1495–1497.
https://doi.org/10.1182/blood-2022-157822
Published: 2022
Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Clinical Trials & Observations
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Journal: Blood
Blood (2021) 138 (21): 2042–2050.
https://doi.org/10.1182/blood.2021012082
Published: 2021
Includes: Supplemental data
Journal Articles

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Elias J. Jabbour, Michael W. Deininger, Elisabetta Abruzzese, Jane F Apperley, Jorge E. Cortes, Charles Chuah, Daniel J. DeAngelo, John F. DiPersio, Andreas Hochhaus, Jeffrey H. Lipton, Franck E. Nicolini, Javier Pinilla Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Michael J. Mauro, Neil P Shah, Moshe Talpaz, Alexander Vorog, Vickie Lu, Hagop Kantarjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 2550.
https://doi.org/10.1182/blood-2021-146175
Published: 2021
Journal Articles

Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues De Lavallade, Jeffrey H. Lipton, Elza Lomaia, James K McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Soledad S. Undurraga, Vickie Lu, Alexander Vorog, Jorge E. Cortes
Journal: Blood
Blood (2021) 138 (Supplement 1): 307.
https://doi.org/10.1182/blood-2021-145995
Published: 2021
Journal Articles

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Yousif Matloub, MD, Lia Gore, MD, Mignon L. Loh, MD, Chin-Hon Pui, MD, Michael J. Hanley, PharmD, PhD, Vickie Lu, PhD, E. Jane Leonard, MSc, Muriel Granier, Andrea Biondi, MD, Lewis B. Silverman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47.
https://doi.org/10.1182/blood-2020-134724
Published: 2020
Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-135883
Published: 2020
Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Hagop M. Kantarjian, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Charles Chuah, MD, Daniel J. DeAngelo, MD PhD, John F. DiPersio, MD PhD, Andreas Hochhaus, MD, Jeffrey H. Lipton, MD PhD, Franck E Nicolini, MDPhD, Javier Pinilla Ibarz, MD PhD, Delphine Rea, MDPhD, Gianantonio Rosti, MD, Philippe Rousselot, MDPhD, Neil P Shah, MD PhD, Moshe Talpaz, MD, Shouryadeep Srivastava, MBBS, PhD, Vickie Lu, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-133922
Published: 2020
Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140482
Published: 2020
Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 902.
https://doi.org/10.1182/blood.V130.Suppl_1.902.902
Published: 2017